Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
GLP-3 vs GLP-1: Triple vs Single Agonist Comparison Chart (2026)
comparison"GLP-3" is informal shorthand for triple-agonist drugs like retatrutide. This chart maps GLP-1 mono, GIP/GLP-1 dual, and triple agonists side by side on mechanism, FDA status, and trial weight loss.
Zepbound vs Wegovy Comparison Chart: Tirzepatide vs Semaglutide
comparisonOne chart, all the numbers that matter. Zepbound (tirzepatide) and Wegovy (semaglutide) compared row by row using SURMOUNT-5 head-to-head data, dosing ladders, cost, and FDA approvals.
Mounjaro vs Zepbound: Same Drug, Different Names (2026)
comparisonMounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.
Wegovy vs Zepbound: Head-to-Head Comparison (SURMOUNT-5 Data)
comparisonSURMOUNT-5 compared tirzepatide and semaglutide head-to-head for the first time. See the weight loss numbers, mechanism differences, dosing schedules, and which drug may fit your situation.
Tirzepatide Calculator & Guide: Mounjaro & Zepbound Dosing (2026)
hubFree tirzepatide dosing calculator plus complete guide. Visualize Mounjaro/Zepbound drug levels, plan titration schedules, understand half-life pharmacokinetics, and manage side effects.